This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

25 Oct 2022

A Comprehensive Pharmaceutical Enterprise with Multi-Field

We are committed to the export of several API and intermediates, such as Azathioprine, Mercaptopurine, Ribavirin etc. 

Zhejiang Cheng Yi Pharmaceutical Co., Ltd. was founded in 1966, and now is a comprehensive modern pharmaceutical enterprise, specializing in the production of pharmaceutical capsules, injections, tablets, APIs, and pharmaceutical intermediates. The company took the lead in carrying out international certification in 1998, and many products have been approved by many countries and regions such as US FDA, EU EMEA, Australia TGA, UK MHRA, Mexico COFEPRIS and so on. As of May 2022, the company has built 9 GMP workshops, 5 chemical laboratories, 1 preparation laboratory, 1 new drug development department, and 1 pilot plant for new product development and production process technique transformation. 

At present, the company can produce more than 70 varieties and nearly 100 specifications of drugs. Among them, Azathioprine, Mercaptopurine, and Ribavirin APIs have been certified by the US FDA and EU GMP several times. The sales market covers more than 20 countries and regions in Europe, America, India, South Africa, and Southeast Asia. At the same time, we also produce marine biomedicine 'glucosamine hydrochloride' series for the treatment and prevention of systemic osteoarthritis. 

In the future, Cheng Yi Pharma will aim at the largest annual production in Asia of 2,000 tons of glucosamine hydrochloride API and 1000 tons of super fish oil (icosapent ethyl) projects, focusing on the Massive Health Industry. The 'Cheng Yi Pharma Marine Biomedicine Manufacturing Project' with an investment of 10 billion yuan has been basically completed. Among them, the trial production of ultra-high-purity fish oil EPA soft capsule was successful at the end of 2021. Next, we will launch a series of API and soft capsule products successively such as EPA, nervonic acid, etc. to realize the whole process, whole category, and industry chain layout from food to health products to medicine, striving to seize the heights of strategic commanding, empowering enterprise the new value, and accomplishing collectivizing and high-quality development of the company. 

Mentioned Companies
Zhejiang Cheng Yi Pharmaceutical Co., Ltd.
View company profile

Related News